Identification

Name
Protriptyline
Accession Number
DB00344  (APRD00441)
Type
Small Molecule
Groups
Approved
Description

Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may cause sedation. In depressed individuals, protriptyline exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Protriptyline may be used for the treatment of depression.

Structure
Thumb
Synonyms
  • 3-(5H-dibenzo[a,d][7]annulen-5-yl)-N-methylpropan-1-amine
  • 3-(5H-Dibenzo[a,D]cyclohepten-5-yl)-N-methyl-1-propanamine
  • 5-(3-Methylaminopropyl)-5H-dibenzo[a,D]cycloheptene
  • 7-(3-Methylaminopropyl)-1,2:5,6-dibenzocycloheptatriene
  • Amimetilina
  • N-Methyl-5H-dibenzo[a,D]cycloheptene-5-propanamine
  • N-Methyl-5H-dibenzo[a,D]cycloheptene-5-propylamine
  • Protriptilina
  • Protriptylin
  • Protriptyline
  • Protriptylinum
External IDs
MK 240 / MK-240
Product Ingredients
IngredientUNIICASInChI Key
Protriptyline hydrochloride44665V00O81225-55-4OGQDIIKRQRZXJH-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Triptil Tab 10mgTablet10 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1966-12-312001-01-25Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Protriptyline HydrochlorideTablet, film coated5 mg/1OralEpic Pharma, LLC2013-01-09Not applicableUs
Protriptyline HydrochlorideTablet, film coated10 mg/1OralRising Pharmaceuticals2010-06-11Not applicableUs
Protriptyline hydrochlorideTablet, film coated5 mg/1OralHi Tech Pharmacal Co., Inc.2013-10-28Not applicableUs
Protriptyline HydrochlorideTablet10 mg/1OralWest Ward Pharmaceutical2008-09-16Not applicableUs
Protriptyline HydrochlorideTablet, film coated5 mg/1OralRising Pharmaceuticals2010-06-11Not applicableUs
Protriptyline HydrochlorideTablet, film coated10 mg/1OralEpic Pharma, LLC2013-01-09Not applicableUs
Protriptyline HydrochlorideTablet5 mg/1OralWest Ward Pharmaceutical2008-09-16Not applicableUs
Protriptyline hydrochlorideTablet, film coated10 mg/1OralHi Tech Pharmacal Co., Inc.2013-10-28Not applicableUs
International/Other Brands
Triptil / Vivactil (Odyssey)
Categories
UNII
4NDU154T12
CAS number
438-60-8
Weight
Average: 263.3767
Monoisotopic: 263.167399677
Chemical Formula
C19H21N
InChI Key
BWPIARFWQZKAIA-UHFFFAOYSA-N
InChI
InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-10,12-13,19-20H,6,11,14H2,1H3
IUPAC Name
methyl(3-{tricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,9,11,13-heptaen-2-yl}propyl)amine
SMILES
CNCCCC1C2=CC=CC=C2C=CC2=CC=CC=C12

Pharmacology

Indication

For the treatment of depression.

Associated Conditions
Pharmacodynamics

Protriptyline is a tricyclic antidepressant. It was thought that tricyclic antidepressants work by inhibiting the reuptake of the neurotransmitters norepinephrine and serotonin by nerve cells. However, this response occurs immediately, yet mood does not lift for approximately two weeks. It is now thought that changes occur in receptor sensitivity in the cerebral cortex and hippocampus. The hippocampus is part of the limbic system, a part of the brain involved in emotions. Presynaptic receptors are affected: α1 and β1 receptors are sensitized, α2 receptors are desensitised (leading to increased noradrenaline production). Tricyclics are also known as effective analgesics for different types of pain, especially neuropathic or neuralgic pain. A precise mechanism for their analgesic action is unknown, but it is thought that they modulate anti-pain opioid systems in the CNS via an indirect serotonergic route. They are also effective in migraine prophylaxis, but not in abortion of acute migraine attack. The mechanism of their anti-migraine action is also thought to be serotonergic.

Mechanism of action

Protriptyline acts by decreasing the reuptake of norepinephrine and serotonin (5-HT).

TargetActionsOrganism
ASodium-dependent noradrenaline transporter
inhibitor
Human
ASodium-dependent serotonin transporter
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination

Cumulative urinary excretion during 16 days accounted for approximately 50% of the drug. The fecal route of excretion did not seem to be important.

Half life
Not Available
Clearance
Not Available
Toxicity

Side effects include anxiety, blood disorders, confusion, decreased libido, dizziness, flushing, headache, impotence, insomnia, low blood pressure, nightmares, rapid or irregular heartbeat, rash, seizures, sensitivity to sunlight, stomach and intestinal discomfort, sedation, hypotension, blurred vision, dry mouth, constipation, urinary retention, postural hypotension, tachycardia, hypertension, ECG changes, heart failure, impaired memory and delirium, and precipitation of hypomanic or manic episodes in bipolar depression. Withdrawal symptoms include gastrointestinal disturbances, anxiety, and insomnia.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2D6CYP2D6*3Not AvailableC alleleEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*4Not AvailableC alleleEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*5Not AvailableWhole-gene deletionEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*6Not Available1707delTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*7Not Available2935A>CEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*8Not Available1758G>TEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*11Not Available883G>CEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*12Not Available124G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*13Not AvailableCYP2D7/2D6 hybrid gene structureEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*14ANot Available1758G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*15Not Available137insT, 137_138insTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*19Not Available2539_2542delAACTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*20Not Available1973_1974insGEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*21Not Available2573insCEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*31Not Available-1770G>A / -1584C>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*36Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*38Not Available2587_2590delGACTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*40Not Available1863_1864ins(TTT CGC CCC)2Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*42Not Available3259_3260insGTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*44Not Available2950G>CEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*47Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*51Not Available-1584C>G / -1235A>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*56Not Available3201C>TEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*57Not Available100C>T / 310G>T  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*62Not Available4044C>TEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*68ANot Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*68BNot AvailableSimilar but not identical switch region compared to CYP2D6*68A. Found in tandem arrangement with CYP2D6*4.Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*69Not Available2988G>A / -1426C>T  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*92Not Available1995delCEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*100Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*101Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer.Details

Interactions

Drug Interactions
DrugInteractionDrug group
(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINEThe serum concentration of Protriptyline can be increased when it is combined with (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE.Experimental
1,10-PhenanthrolineThe serum concentration of Protriptyline can be increased when it is combined with 1,10-Phenanthroline.Experimental
2,5-Dimethoxy-4-ethylamphetamineProtriptyline may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineProtriptyline may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-DichloroisocoumarinThe serum concentration of Protriptyline can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
3,4-MethylenedioxyamphetamineProtriptyline may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-(2-Aminoethyl)Benzenesulfonyl FluorideThe serum concentration of Protriptyline can be increased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.Experimental
4-Bromo-2,5-dimethoxyamphetamineProtriptyline may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineProtriptyline may decrease the antihypertensive activities of 4-Methoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Protriptyline is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Protriptyline.Experimental
AbediterolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Abediterol.Investigational
AbirateroneThe serum concentration of Protriptyline can be increased when it is combined with Abiraterone.Approved
AcenocoumarolProtriptyline may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Aceprometazine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Acetophenazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Protriptyline is combined with Adipiplon.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Protriptyline.Approved
AgmatineProtriptyline may decrease the antihypertensive activities of Agmatine.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Protriptyline is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Protriptyline.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Protriptyline is combined with Almotriptan.Approved, Investigational
AlogliptinThe serum concentration of Protriptyline can be increased when it is combined with Alogliptin.Approved
AlosetronAlosetron may increase the serotonergic activities of Protriptyline.Approved, Withdrawn
Alpha-1-proteinase inhibitorThe serum concentration of Protriptyline can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Protriptyline.Approved, Illicit, Investigational
AltretamineAltretamine may increase the orthostatic hypotensive activities of Protriptyline.Approved
AmiodaroneThe metabolism of Protriptyline can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Protriptyline is combined with Amisulpride.Approved, Investigational
AmitrazProtriptyline may decrease the antihypertensive activities of Amitraz.Vet Approved
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Protriptyline.Approved
AmobarbitalThe metabolism of Protriptyline can be increased when combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Protriptyline is combined with Amperozide.Experimental
AmphetamineAmphetamine may increase the serotonergic activities of Protriptyline.Approved, Illicit, Investigational
AmprenavirThe serum concentration of Protriptyline can be increased when it is combined with Amprenavir.Approved, Investigational
AnagrelideProtriptyline may increase the QTc-prolonging activities of Anagrelide.Approved
Antithrombin III humanThe serum concentration of Protriptyline can be increased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Protriptyline can be increased when it is combined with Apixaban.Approved
ApomorphineProtriptyline may decrease the antihypertensive activities of Apomorphine.Approved, Investigational
ApraclonidineProtriptyline may decrease the antihypertensive activities of Apraclonidine.Approved
AprotininThe serum concentration of Protriptyline can be increased when it is combined with Aprotinin.Approved, Investigational, Withdrawn
ArbutamineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Arformoterol.Approved, Investigational
ArgatrobanThe serum concentration of Protriptyline can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Protriptyline.Approved, Investigational
Arsenic trioxideProtriptyline may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherProtriptyline may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Articaine.Approved
AsenapineProtriptyline may increase the QTc-prolonging activities of Asenapine.Approved
AsunaprevirThe serum concentration of Protriptyline can be increased when it is combined with Asunaprevir.Approved, Investigational, Withdrawn
AtazanavirThe serum concentration of Protriptyline can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Protriptyline can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Azaperone.Investigational, Vet Approved
AzelastineProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzithromycinProtriptyline may increase the QTc-prolonging activities of Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Protriptyline.Approved
BambuterolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Bambuterol.Approved, Investigational
BarbexacloneThe metabolism of Protriptyline can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Protriptyline can be increased when combined with Barbital.Illicit
BatimastatThe serum concentration of Protriptyline can be increased when it is combined with Batimastat.Experimental
BedaquilineProtriptyline may increase the QTc-prolonging activities of Bedaquiline.Approved
BenazeprilThe serum concentration of Protriptyline can be increased when it is combined with Benazepril.Approved, Investigational
BenmoxinBenmoxin may increase the serotonergic activities of Protriptyline.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Benperidol.Approved, Investigational
BenzamidineThe serum concentration of Protriptyline can be increased when it is combined with Benzamidine.Experimental
BenzocaineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Benzocaine.Approved, Investigational
BenzphetamineProtriptyline may decrease the antihypertensive activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Protriptyline is combined with Benzyl alcohol.Approved
BetaxololThe metabolism of Protriptyline can be decreased when combined with Betaxolol.Approved, Investigational
BethanidineProtriptyline may decrease the antihypertensive activities of Bethanidine.Approved
BifeprunoxThe risk or severity of adverse effects can be increased when Protriptyline is combined with Bifeprunox.Investigational
BitolterolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Bitolterol.Withdrawn
BivalirudinThe serum concentration of Protriptyline can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Protriptyline can be increased when it is combined with Boceprevir.Approved, Withdrawn
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Protriptyline.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Protriptyline.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Protriptyline is combined with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.Approved
BrofaromineBrofaromine may increase the serotonergic activities of Protriptyline.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Protriptyline.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Protriptyline is combined with Bromisoval.Experimental
BromocriptineProtriptyline may decrease the antihypertensive activities of Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Protriptyline is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Bupivacaine.Approved, Investigational
BuprenorphineProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Protriptyline can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Protriptyline is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Protriptyline.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Protriptyline.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Protriptyline is combined with Butamben.Approved, Withdrawn
ButaperazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Protriptyline is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Protriptyline.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Protriptyline.Approved
CamostatThe serum concentration of Protriptyline can be increased when it is combined with Camostat.Experimental
CandoxatrilThe serum concentration of Protriptyline can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Protriptyline can be increased when it is combined with Candoxatrilat.Experimental
CanertinibThe risk or severity of adverse effects can be increased when Protriptyline is combined with Canertinib.Investigational
CaptoprilThe serum concentration of Protriptyline can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Protriptyline can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Protriptyline is combined with Carfentanil.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Cariprazine.Approved, Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Carisoprodol.Approved
CaroxazoneCaroxazone may increase the serotonergic activities of Protriptyline.Withdrawn
CelecoxibThe metabolism of Protriptyline can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololThe risk or severity of adverse effects can be increased when Protriptyline is combined with Celiprolol.Approved, Investigational
CeritinibProtriptyline may increase the QTc-prolonging activities of Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Protriptyline.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Protriptyline is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Protriptyline.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Chloroprocaine.Approved
ChloroquineThe metabolism of Protriptyline can be decreased when combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Chlorphenamine.Approved
ChlorphentermineProtriptyline may increase the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Chlorproethazine.Experimental
ChlorpromazineThe metabolism of Protriptyline can be decreased when combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Protriptyline can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
ChymostatinThe serum concentration of Protriptyline can be increased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Protriptyline can be increased when it is combined with Cilastatin.Approved, Investigational
CilazaprilThe serum concentration of Protriptyline can be increased when it is combined with Cilazapril.Approved
CimetidineThe metabolism of Protriptyline can be decreased when combined with Cimetidine.Approved, Investigational
CinacalcetThe serum concentration of Protriptyline can be increased when it is combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Cinchocaine.Approved, Vet Approved
CiprofloxacinProtriptyline may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CirazolineProtriptyline may increase the vasopressor activities of Cirazoline.Experimental
CisaprideProtriptyline may increase the arrhythmogenic activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramThe risk or severity of adverse effects can be increased when Protriptyline is combined with Citalopram.Approved
ClarithromycinProtriptyline may increase the QTc-prolonging activities of Clarithromycin.Approved
ClemastineThe metabolism of Protriptyline can be decreased when combined with Clemastine.Approved, Investigational
ClenbuterolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClidiniumThe risk or severity of adverse effects can be increased when Protriptyline is combined with Clidinium.Approved
ClobazamThe metabolism of Protriptyline can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Protriptyline is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Protriptyline is combined with Clonazepam.Approved, Illicit
ClonidineProtriptyline may decrease the antihypertensive activities of Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Protriptyline.Approved, Illicit
ClorindioneProtriptyline may increase the anticoagulant activities of Clorindione.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Protriptyline can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Protriptyline can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Protriptyline can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Protriptyline can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Protriptyline.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Protriptyline.Approved
CrizotinibProtriptyline may increase the QTc-prolonging activities of Crizotinib.Approved
CurcuminThe metabolism of Protriptyline can be decreased when combined with Curcumin.Approved, Investigational
CyamemazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Cyclobenzaprine.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Cyclopropane.Experimental
CyproheptadineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Cyproheptadine.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Protriptyline.Approved
DantroleneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Dantrolene.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Protriptyline is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Protriptyline.Investigational
DarexabanThe serum concentration of Protriptyline can be increased when it is combined with Darexaban.Investigational
DarifenacinThe metabolism of Protriptyline can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Protriptyline can be increased when it is combined with Darunavir.Approved
DelanzomibThe serum concentration of Protriptyline can be increased when it is combined with Delanzomib.Investigational
DelaprilThe serum concentration of Protriptyline can be increased when it is combined with Delapril.Investigational
DelavirdineThe metabolism of Protriptyline can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Protriptyline.Approved
DesipramineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Desipramine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Protriptyline is combined with Desmopressin.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Desvenlafaxine.Approved, Investigational
DetomidineProtriptyline may decrease the antihypertensive activities of Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Dexbrompheniramine.Approved
DexmedetomidineProtriptyline may decrease the antihypertensive activities of Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Protriptyline.Approved, Investigational
DextroamphetamineProtriptyline may increase the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Protriptyline is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Protriptyline is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Protriptyline.Approved, Illicit, Investigational, Vet Approved
DicoumarolProtriptyline may increase the anticoagulant activities of Dicoumarol.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Protriptyline is combined with Diethyl ether.Experimental
DiethylpropionProtriptyline may increase the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Protriptyline is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Protriptyline.Approved, Illicit
DihydroergotamineProtriptyline may decrease the antihypertensive activities of Dihydroergotamine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Protriptyline is combined with Dimenhydrinate.Approved
DiphenadioneProtriptyline may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe metabolism of Protriptyline can be decreased when combined with Diphenhydramine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Protriptyline.Approved, Illicit
DipivefrinProtriptyline may decrease the antihypertensive activities of Dipivefrin.Approved
DisopyramideProtriptyline may increase the QTc-prolonging activities of Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Dixyrazine.Experimental
DL-MethylephedrineProtriptyline may decrease the antihypertensive activities of DL-Methylephedrine.Approved
DobutamineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Dobutamine.Approved
DofetilideProtriptyline may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
DolasetronProtriptyline may increase the QTc-prolonging activities of Dolasetron.Approved, Investigational
DomperidoneProtriptyline may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Protriptyline is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Protriptyline can be decreased when combined with Dosulepin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Protriptyline is combined with Doxepin.Approved, Investigational
DoxofyllineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Doxofylline.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Protriptyline.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Protriptyline is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.Approved, Illicit
DronedaroneProtriptyline may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Drotebanol.Experimental, Illicit
DroxidopaProtriptyline may decrease the antihypertensive activities of Droxidopa.Approved, Investigational
DuloxetineDuloxetine may increase the serotonergic activities of Protriptyline.Approved
DyclonineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Dyclonine.Approved
EcabetThe serum concentration of Protriptyline can be increased when it is combined with Ecabet.Approved, Investigational
EcgonineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Protriptyline.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Protriptyline is combined with Efavirenz.Approved, Investigational
ElafinThe serum concentration of Protriptyline can be increased when it is combined with Elafin.Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Protriptyline.Approved, Investigational
EliglustatProtriptyline may increase the QTc-prolonging activities of Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Eltanolone.Investigational
EnalaprilThe serum concentration of Protriptyline can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Protriptyline can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Protriptyline can be increased when it is combined with Enalkiren.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Protriptyline is combined with Entacapone.Approved, Investigational
EphedraProtriptyline may decrease the antihypertensive activities of Ephedra.Approved, Nutraceutical, Withdrawn
EpinephrineProtriptyline may decrease the antihypertensive activities of Epinephrine.Approved, Vet Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ergonovine.Approved
ErgotamineProtriptyline may decrease the antihypertensive activities of Ergotamine.Approved
ErythromycinProtriptyline may increase the QTc-prolonging activities of Erythromycin.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Protriptyline is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Protriptyline.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Protriptyline.Approved, Investigational
EtafedrineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Etafedrine.Approved
EthanolProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ethotoin.Approved
Ethyl biscoumacetateProtriptyline may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Protriptyline is combined with Etizolam.Approved
EtomidateProtriptyline may decrease the antihypertensive activities of Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Etorphine.Illicit, Vet Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Protriptyline.Approved
EzogabineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ezogabine.Approved, Investigational
FaldaprevirThe serum concentration of Protriptyline can be increased when it is combined with Faldaprevir.Investigational
FelbamateThe risk or severity of adverse effects can be increased when Protriptyline is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoterolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Fenoterol.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Protriptyline is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Fexofenadine.Approved, Investigational
FlecainideProtriptyline may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Protriptyline is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Protriptyline is combined with Fludiazepam.Approved, Illicit
FluindioneProtriptyline may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Protriptyline is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Protriptyline.Approved, Vet Approved
FlupentixolProtriptyline may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Protriptyline.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Protriptyline.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Protriptyline is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Protriptyline.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Formoterol.Approved, Investigational
FosamprenavirThe serum concentration of Protriptyline can be increased when it is combined with Fosamprenavir.Approved
FosinoprilThe serum concentration of Protriptyline can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Protriptyline is combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Fospropofol.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Protriptyline is combined with Frovatriptan.Approved, Investigational
FurazolidoneFurazolidone may increase the serotonergic activities of Protriptyline.Approved, Investigational, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Protriptyline.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Protriptyline is combined with Gabapentin Enacarbil.Approved, Investigational
GabexateThe serum concentration of Protriptyline can be increased when it is combined with Gabexate.Investigational
Gadobenic acidProtriptyline may increase the QTc-prolonging activities of Gadobenic acid.Approved, Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Protriptyline.Approved, Illicit, Investigational
GeldanamycinThe serum concentration of Protriptyline can be increased when it is combined with Geldanamycin.Experimental, Investigational
GemifloxacinProtriptyline may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepefrineProtriptyline may increase the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Protriptyline is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Protriptyline is combined with Glutethimide.Approved, Illicit
GM6001The serum concentration of Protriptyline can be increased when it is combined with GM6001.Experimental
GoserelinProtriptyline may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronProtriptyline may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GuanabenzProtriptyline may decrease the antihypertensive activities of Guanabenz.Approved, Investigational
GuanfacineProtriptyline may decrease the antihypertensive activities of Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Protriptyline is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe metabolism of Protriptyline can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Halothane.Approved, Vet Approved
HarmalineHarmaline may increase the serotonergic activities of Protriptyline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Protriptyline is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe metabolism of Protriptyline can be increased when combined with Hexobarbital.Approved
HexoprenalineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Hexoprenaline.Approved, Withdrawn
HydracarbazineHydracarbazine may increase the serotonergic activities of Protriptyline.Experimental
HydrocodoneProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Protriptyline.Approved, Illicit
HydroxyamphetamineProtriptyline may increase the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.Approved
IbutilideProtriptyline may increase the QTc-prolonging activities of Ibutilide.Approved
IdraparinuxThe serum concentration of Protriptyline can be increased when it is combined with Idraparinux.Investigational
IloperidoneProtriptyline may increase the QTc-prolonging activities of Iloperidone.Approved
ImidaprilThe serum concentration of Protriptyline can be increased when it is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Imipramine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Indacaterol.Approved
IndalpineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Indalpine.Investigational, Withdrawn
IndinavirThe serum concentration of Protriptyline can be increased when it is combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Protriptyline is combined with Indiplon.Investigational
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Protriptyline.Approved, Investigational
Iofetamine I-123Protriptyline may increase the stimulatory activities of Iofetamine I-123.Approved
IproclozideIproclozide may increase the serotonergic activities of Protriptyline.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Protriptyline.Withdrawn
IsocarboxazidThe therapeutic efficacy of Protriptyline can be increased when used in combination with Isocarboxazid.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Protriptyline.Approved, Vet Approved
IsoflurophateThe serum concentration of Protriptyline can be increased when it is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsomethepteneProtriptyline may increase the vasopressor activities of Isometheptene.Approved
IsoniazidThe metabolism of Protriptyline can be decreased when combined with Isoniazid.Approved, Investigational
IsoprenalineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Isoprenaline.Approved, Investigational
IxazomibThe serum concentration of Protriptyline can be increased when it is combined with Ixazomib.Approved, Investigational
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Protriptyline.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Protriptyline can be decreased when combined with Ketoconazole.Approved, Investigational
L-TryptophanL-Tryptophan may increase the serotonergic activities of Protriptyline.Approved, Nutraceutical, Withdrawn
LamotrigineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Lamotrigine.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Protriptyline.Approved
LenvatinibProtriptyline may increase the QTc-prolonging activities of Lenvatinib.Approved, Investigational
LepirudinThe serum concentration of Protriptyline can be increased when it is combined with Lepirudin.Approved
LetaxabanThe serum concentration of Protriptyline can be increased when it is combined with Letaxaban.Investigational
LeuprolideProtriptyline may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Protriptyline is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Protriptyline is combined with Levodopa.Approved
LevofloxacinProtriptyline may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Protriptyline is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Protriptyline is combined with Levomilnacipran.Approved, Investigational
LevonordefrinProtriptyline may decrease the antihypertensive activities of Levonordefrin.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Protriptyline.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Levosalbutamol.Approved, Investigational
LevothyroxineLevothyroxine may increase the arrhythmogenic activities of Protriptyline.Approved
LidocaineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Protriptyline can be increased when it is combined with Linagliptin.Approved
LinezolidLinezolid may increase the serotonergic activities of Protriptyline.Approved, Investigational
LiothyronineLiothyronine may increase the arrhythmogenic activities of Protriptyline.Approved, Vet Approved
LiotrixLiotrix may increase the arrhythmogenic activities of Protriptyline.Approved
LisdexamfetamineProtriptyline may increase the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisinoprilThe serum concentration of Protriptyline can be increased when it is combined with Lisinopril.Approved, Investigational
Lithium cationLithium may increase the neurotoxic activities of Protriptyline.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Protriptyline is combined with Lofentanil.Illicit
LofexidineThe therapeutic efficacy of Protriptyline can be increased when used in combination with Lofexidine.Approved, Investigational
LopinavirThe metabolism of Protriptyline can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Protriptyline is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Loratadine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Protriptyline.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Protriptyline is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Protriptyline is combined with Lormetazepam.Approved
LorpiprazoleThe serum concentration of Protriptyline can be increased when it is combined with Lorpiprazole.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Protriptyline.Approved
LumefantrineProtriptyline may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Protriptyline.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Protriptyline can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineThe metabolism of Protriptyline can be decreased when combined with Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Maprotiline.Approved, Investigational
MebanazineMebanazine may increase the serotonergic activities of Protriptyline.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Protriptyline is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Protriptyline is combined with Medazepam.Experimental
MedetomidineProtriptyline may decrease the antihypertensive activities of Medetomidine.Vet Approved
MelagatranThe serum concentration of Protriptyline can be increased when it is combined with Melagatran.Experimental
MelatoninThe risk or severity of adverse effects can be increased when Protriptyline is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Melperone.Approved, Investigational
MephedroneProtriptyline may increase the stimulatory activities of Mephedrone.Investigational
MephentermineProtriptyline may increase the vasopressor activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Protriptyline.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Mesoridazine.Approved, Investigational
MetaraminolProtriptyline may increase the vasopressor activities of Metaraminol.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Protriptyline.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Protriptyline is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineProtriptyline may decrease the antihypertensive activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe metabolism of Protriptyline can be increased when combined with Methohexital.Approved
MethotrimeprazineProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxamineProtriptyline may increase the vasopressor activities of Methoxamine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineProtriptyline may increase the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Protriptyline is combined with Methsuximide.Approved
MethyldopaProtriptyline may decrease the antihypertensive activities of Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Methylecgonine.Experimental
Methylene blueProtriptyline may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Protriptyline.Approved, Investigational
MethylphenobarbitalThe metabolism of Protriptyline can be increased when combined with Methylphenobarbital.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Protriptyline.Approved, Investigational
MetoprololThe metabolism of Protriptyline can be decreased when combined with Metoprolol.Approved, Investigational
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Protriptyline.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Protriptyline.Approved, Illicit
MidodrineProtriptyline may increase the vasopressor activities of Midodrine.Approved
MidomafetamineProtriptyline may increase the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Protriptyline can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneMifepristone may increase the QTc-prolonging activities of Protriptyline.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Protriptyline is combined with Milnacipran.Approved, Investigational
MinaprineMinaprine may increase the serotonergic activities of Protriptyline.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.Approved, Investigational
MirabegronThe metabolism of Protriptyline can be decreased when combined with Mirabegron.Approved
MirtazapineProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAProtriptyline may increase the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideMoclobemide may increase the serotonergic activities of Protriptyline.Approved, Investigational
MoexiprilThe serum concentration of Protriptyline can be increased when it is combined with Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Moperone.Experimental
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Protriptyline.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Mosapramine.Experimental
MoxifloxacinProtriptyline may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Protriptyline.Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Protriptyline can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.Approved, Investigational
NafamostatThe serum concentration of Protriptyline can be increased when it is combined with Nafamostat.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Protriptyline.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Protriptyline.Approved
NaphazolineProtriptyline may decrease the antihypertensive activities of Naphazoline.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Protriptyline is combined with Naratriptan.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Protriptyline can be increased when it is combined with Nelfinavir.Approved
NevirapineThe metabolism of Protriptyline can be decreased when combined with Nevirapine.Approved
NialamideNialamide may increase the serotonergic activities of Protriptyline.Withdrawn
NicardipineThe metabolism of Protriptyline can be decreased when combined with Nicardipine.Approved, Investigational
NicorandilProtriptyline may increase the hypotensive activities of Nicorandil.Approved, Investigational
NilotinibProtriptyline may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Protriptyline.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Protriptyline.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Protriptyline is combined with Nordazepam.Approved
NorepinephrineProtriptyline may decrease the antihypertensive activities of Norepinephrine.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Nortriptyline.Approved
OctamoxinOctamoxin may increase the serotonergic activities of Protriptyline.Withdrawn
OfloxacinProtriptyline may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Protriptyline.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Olodaterol.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Olopatadine.Approved
OmapatrilatThe serum concentration of Protriptyline can be increased when it is combined with Omapatrilat.Investigational
OndansetronProtriptyline may increase the QTc-prolonging activities of Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Protriptyline is combined with Opium.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Orciprenaline.Approved
OrphenadrineProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Protriptyline is combined with Osanetant.Investigational
OtamixabanThe serum concentration of Protriptyline can be increased when it is combined with Otamixaban.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Protriptyline.Approved
OxprenololThe risk or severity of adverse effects can be increased when Protriptyline is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Protriptyline.Approved, Illicit, Investigational
OxymetazolineProtriptyline may decrease the antihypertensive activities of Oxymetazoline.Approved, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Protriptyline.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Oxypertine.Experimental
PaliperidoneProtriptyline may decrease the antihypertensive activities of Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Protriptyline.Approved, Investigational
PanobinostatThe serum concentration of Protriptyline can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
PargylinePargyline may increase the serotonergic activities of Protriptyline.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Protriptyline.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Protriptyline.Approved
Peginterferon alfa-2bThe serum concentration of Protriptyline can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Penfluridol.Experimental
PentamidineProtriptyline may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Protriptyline.Approved, Vet Approved
PentobarbitalThe metabolism of Protriptyline can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.Approved
PerazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Perazine.Approved, Investigational
PerflutrenProtriptyline may increase the QTc-prolonging activities of Perflutren.Approved
PergolideProtriptyline may decrease the antihypertensive activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe serum concentration of Protriptyline can be increased when it is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Protriptyline is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Protriptyline.Approved
PethidineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Pethidine.Approved
PF-00610355The risk or severity of adverse effects can be increased when Protriptyline is combined with PF-00610355.Investigational
PhenazocineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Phenazocine.Experimental
PhendimetrazineProtriptyline may increase the vasopressor activities of Phendimetrazine.Approved, Illicit
PhenelzinePhenelzine may increase the serotonergic activities of Protriptyline.Approved
PhenibutThe risk or severity of adverse effects can be increased when Protriptyline is combined with Phenibut.Experimental
PhenindioneProtriptyline may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniprazinePheniprazine may increase the serotonergic activities of Protriptyline.Withdrawn
PhenobarbitalThe metabolism of Protriptyline can be increased when combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Phenoxyethanol.Approved
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Protriptyline.Withdrawn
PhenprocoumonProtriptyline may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhentermineProtriptyline may increase the stimulatory activities of Phentermine.Approved, Illicit
PhenylephrineProtriptyline may increase the vasopressor activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Protriptyline.Approved, Vet Approved
PhosphoramidonThe serum concentration of Protriptyline can be increased when it is combined with Phosphoramidon.Experimental
PimozideProtriptyline may increase the QTc-prolonging activities of Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Pipotiazine.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Protriptyline is combined with Piritramide.Approved, Investigational
PirlindolePirlindole may increase the serotonergic activities of Protriptyline.Approved
PitolisantThe therapeutic efficacy of Pitolisant can be decreased when used in combination with Protriptyline.Approved, Investigational
PivhydrazinePivhydrazine may increase the serotonergic activities of Protriptyline.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Protriptyline is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Protriptyline is combined with Pomalidomide.Approved
PramipexoleProtriptyline may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Protriptyline is combined with Prazepam.Approved, Illicit
PregabalinThe therapeutic efficacy of Protriptyline can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Prilocaine.Approved
PrimaquineProtriptyline may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Protriptyline can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Protriptyline can be increased when it is combined with Prinomastat.Investigational
ProcainamideProtriptyline may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineProcaine may increase the serotonergic activities of Protriptyline.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the serotonergic activities of Protriptyline.Approved, Investigational
ProcaterolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Procaterol.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Protriptyline.Approved, Vet Approved
PromazineThe metabolism of Protriptyline can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Promethazine.Approved, Investigational
PropafenoneProtriptyline may increase the QTc-prolonging activities of Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Protriptyline is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Proparacaine.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Propericiazine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Protriptyline.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Propoxycaine.Approved
ProthipendylThe risk or severity of adverse effects can be increased when Protriptyline is combined with Prothipendyl.Investigational
ProtokylolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Protokylol.Approved, Vet Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Protriptyline is combined with Proxibarbal.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Protriptyline is combined with PSD502.Investigational
PseudoephedrineProtriptyline may decrease the antihypertensive activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Protriptyline.Approved, Illicit
QuetiapineProtriptyline may increase the QTc-prolonging activities of Quetiapine.Approved
QuinaprilThe serum concentration of Protriptyline can be increased when it is combined with Quinapril.Approved, Investigational
QuinidineProtriptyline may increase the QTc-prolonging activities of Quinidine.Approved, Investigational
QuinineProtriptyline may increase the QTc-prolonging activities of Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Quinisocaine.Experimental
RacecadotrilThe serum concentration of Protriptyline can be increased when it is combined with Racecadotril.Investigational
RacepinephrineProtriptyline may decrease the antihypertensive activities of Racepinephrine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Protriptyline is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ramelteon.Approved, Investigational
RamiprilThe serum concentration of Protriptyline can be increased when it is combined with Ramipril.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Protriptyline.Approved, Investigational
RasagilineRasagiline may increase the serotonergic activities of Protriptyline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Protriptyline.Approved
RemikirenThe serum concentration of Protriptyline can be increased when it is combined with Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Protriptyline is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Protriptyline.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Protriptyline.Approved, Investigational
RisperidoneProtriptyline may decrease the antihypertensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ritanserin.Investigational
RitobegronProtriptyline may increase the stimulatory activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ritodrine.Approved, Investigational
RitonavirThe metabolism of Protriptyline can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Protriptyline can be increased when it is combined with Rivaroxaban.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Protriptyline is combined with Rizatriptan.Approved
RolapitantThe metabolism of Protriptyline can be decreased when combined with Rolapitant.Approved, Investigational
RomifidineProtriptyline may decrease the antihypertensive activities of Romifidine.Vet Approved
RopiniroleProtriptyline may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ropivacaine.Approved
RotigotineProtriptyline may increase the sedative activities of Rotigotine.Approved
RucaparibThe metabolism of Protriptyline can be decreased when combined with Rucaparib.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Protriptyline.Approved
S-3304The serum concentration of Protriptyline can be increased when it is combined with S-3304.Investigational
SafrazineSafrazine may increase the serotonergic activities of Protriptyline.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Salmeterol.Approved
SaquinavirThe serum concentration of Protriptyline can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Protriptyline can be increased when it is combined with Saxagliptin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Scopolamine.Approved, Investigational
SecobarbitalThe metabolism of Protriptyline can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the serotonergic activities of Protriptyline.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Protriptyline is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Protriptyline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Protriptyline.Approved, Vet Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Protriptyline.Approved
SimeprevirThe serum concentration of Protriptyline can be increased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Protriptyline can be increased when it is combined with Sitagliptin.Approved, Investigational
SivelestatThe serum concentration of Protriptyline can be increased when it is combined with Sivelestat.Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.Approved
Sodium phosphate, monobasicThe risk or severity of adverse effects can be increased when Protriptyline is combined with Sodium phosphate.Approved
SotalolProtriptyline may increase the QTc-prolonging activities of Sotalol.Approved
SpiraprilThe serum concentration of Protriptyline can be increased when it is combined with Spirapril.Approved
St. John's WortThe metabolism of Protriptyline can be increased when combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe metabolism of Protriptyline can be decreased when combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Protriptyline.Approved, Investigational
SulfisoxazoleProtriptyline may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Protriptyline is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Protriptyline is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Protriptyline is combined with Sumatriptan.Approved, Investigational
SuvorexantProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Protriptyline is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Protriptyline is combined with Tasimelteon.Approved, Investigational
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Protriptyline.Approved
TelaprevirThe serum concentration of Protriptyline can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelavancinProtriptyline may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinProtriptyline may increase the QTc-prolonging activities of Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Protriptyline.Approved, Investigational
TemocaprilThe serum concentration of Protriptyline can be increased when it is combined with Temocapril.Experimental, Investigational
TerbinafineThe metabolism of Protriptyline can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Terbutaline.Approved
TetrabenazineProtriptyline may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Protriptyline is combined with Tetrodotoxin.Investigational
TetryzolineProtriptyline may increase the vasopressor activities of Tetryzoline.Approved
ThalidomideProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe metabolism of Protriptyline can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Protriptyline can be increased when combined with Thiopental.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Protriptyline is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Thioproperazine.Approved
ThioridazineThe metabolism of Protriptyline can be decreased when combined with Thioridazine.Approved, Withdrawn
ThiorphanThe serum concentration of Protriptyline can be increased when it is combined with Thiorphan.Experimental
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Protriptyline.Approved
Thyroid, porcineThyroid, porcine may increase the arrhythmogenic activities of Protriptyline.Approved
TiagabineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Tiagabine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Protriptyline is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Protriptyline can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Tilidine.Experimental
TioclomarolProtriptyline may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirThe metabolism of Protriptyline can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineProtriptyline may decrease the antihypertensive activities of Tizanidine.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Protriptyline.Approved, Withdrawn
ToloxatoneToloxatone may increase the serotonergic activities of Protriptyline.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Protriptyline.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Protriptyline.Approved, Investigational
ToremifeneProtriptyline may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TramadolProtriptyline may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
TrandolaprilThe serum concentration of Protriptyline can be increased when it is combined with Trandolapril.Approved
TranylcypromineTranylcypromine may increase the serotonergic activities of Protriptyline.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Protriptyline.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Protriptyline.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Protriptyline is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Protriptyline.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Triprolidine.Approved
TropisetronTropisetron may increase the serotonergic activities of Protriptyline.Approved, Investigational
UbenimexThe serum concentration of Protriptyline can be increased when it is combined with Ubenimex.Experimental, Investigational
UlinastatinThe serum concentration of Protriptyline can be increased when it is combined with Ulinastatin.Investigational
Valproic AcidThe serum concentration of Protriptyline can be increased when it is combined with Valproic Acid.Approved, Investigational
VandetanibProtriptyline may increase the QTc-prolonging activities of Vandetanib.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Protriptyline.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Protriptyline.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Protriptyline is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Protriptyline is combined with Vigabatrin.Approved
VilanterolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Vilanterol.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Protriptyline.Approved
VildagliptinThe serum concentration of Protriptyline can be increased when it is combined with Vildagliptin.Approved, Investigational
VincristineThe excretion of Vincristine can be decreased when combined with Protriptyline.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Protriptyline is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Protriptyline.Approved, Investigational
WarfarinProtriptyline may increase the anticoagulant activities of Warfarin.Approved
XenonThe risk or severity of adverse effects can be increased when Protriptyline is combined with Xenon.Experimental
XimelagatranThe serum concentration of Protriptyline can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylazineProtriptyline may decrease the antihypertensive activities of Xylazine.Vet Approved
XylometazolineProtriptyline may decrease the antihypertensive activities of Xylometazoline.Approved, Investigational
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Protriptyline.Approved, Investigational, Vet Approved
Z-Val-Ala-Asp fluoromethyl ketoneThe serum concentration of Protriptyline can be increased when it is combined with Z-Val-Ala-Asp fluoromethyl ketone.Experimental
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Protriptyline.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Zimelidine.Withdrawn
ZiprasidoneProtriptyline may increase the QTc-prolonging activities of Ziprasidone.Approved
ZofenoprilThe serum concentration of Protriptyline can be increased when it is combined with Zofenopril.Experimental
ZolazepamThe risk or severity of adverse effects can be increased when Protriptyline is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Protriptyline.Approved, Investigational
ZolpidemProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Protriptyline is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Protriptyline.Approved
ZotepineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolProtriptyline may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0014488
KEGG Compound
C07408
PubChem Compound
4976
PubChem Substance
46505128
ChemSpider
4805
BindingDB
50176062
ChEBI
8597
ChEMBL
CHEMBL668
Therapeutic Targets Database
DAP000863
PharmGKB
PA451168
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Protriptyline
ATC Codes
N06AA11 — Protriptyline

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableCompletedTreatmentDepression1

Pharmacoeconomics

Manufacturers
  • Sanofi aventis us llc
  • Pfizer laboratories div pfizer inc
  • Roxane laboratories inc
  • Sigmapharm laboratories llc
  • Odyssey pharmaceuticals inc
Packagers
  • Barr Pharmaceuticals
  • Duramed
  • Mallinckrodt Inc.
  • Pliva Inc.
  • Qualitest
  • Rising Pharmaceuticals
  • Roxane Labs
  • Sanofi-Aventis Inc.
Dosage forms
FormRouteStrength
TabletOral10 mg/1
TabletOral5 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral5 mg/1
TabletOral10 mg
Prices
Unit descriptionCostUnit
Tofranil-PM 30 125 mg capsule Bottle588.33USD bottle
Tofranil-PM 30 150 mg capsule Bottle588.33USD bottle
Tofranil-PM 30 75 mg capsule Bottle588.33USD bottle
Tofranil 30 50 mg tablet Bottle185.09USD bottle
Tofranil-pm 100 mg capsule19.23USD capsule
Tofranil-pm 150 mg capsule18.86USD capsule
Tofranil-pm 75 mg capsule18.86USD capsule
Tofranil-pm 125 mg capsule18.68USD capsule
Anafranil 25 mg capsule13.51USD capsule
Anafranil 50 mg capsule13.51USD capsule
Anafranil 75 mg capsule13.24USD capsule
Tofranil 50 mg tablet6.64USD tablet
Norpramin 150 mg tablet6.23USD tablet
Surmontil 100 mg capsule5.92USD capsule
Tofranil 25 mg tablet4.97USD tablet
Tofranil 10 mg tablet4.73USD tablet
Norpramin 100 mg tablet4.27USD tablet
Surmontil 50 mg capsule4.15USD capsule
Vivactil 10 mg tablet4.05USD tablet
Norpramin 75 mg tablet3.27USD tablet
Protriptyline hcl 10 mg tablet3.07USD tablet
Vivactil 5 mg tablet2.86USD tablet
Norpramin 50 mg tablet2.59USD tablet
Surmontil 25 mg capsule2.49USD capsule
Protriptyline hcl 5 mg tablet2.12USD tablet
Norpramin 25 mg tablet1.4USD tablet
Norpramin 10 mg tablet1.16USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)169-171 °C (Protriptyline HCl)Not Available
water solubility1.04 mg/LNot Available
logP4.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000231 mg/mLALOGPS
logP4.65ALOGPS
logP4.5ChemAxon
logS-6.1ALOGPS
pKa (Strongest Basic)10.54ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area12.03 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity87.3 m3·mol-1ChemAxon
Polarizability31.6 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9862
Caco-2 permeable+0.7821
P-glycoprotein substrateSubstrate0.7406
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IIInhibitor0.5597
Renal organic cation transporterInhibitor0.6622
CYP450 2C9 substrateNon-substrate0.7206
CYP450 2D6 substrateSubstrate0.9034
CYP450 3A4 substrateSubstrate0.5285
CYP450 1A2 substrateNon-inhibitor0.7595
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8933
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.641
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7512
Ames testNon AMES toxic0.6
CarcinogenicityNon-carcinogens0.9322
BiodegradationNot ready biodegradable0.7732
Rat acute toxicity3.0087 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.736
hERG inhibition (predictor II)Inhibitor0.8132
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-006x-8910000000-ec599ee02d998905757e
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dibenzocycloheptenes. These are compounds containing a dibenzocycloheptene moiety, which consists of two benzene rings connected by a cycloheptene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Dibenzocycloheptenes
Sub Class
Not Available
Direct Parent
Dibenzocycloheptenes
Alternative Parents
Aralkylamines / Dialkylamines / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Dibenzocycloheptene / Aralkylamine / Secondary amine / Secondary aliphatic amine / Organic nitrogen compound / Organopnictogen compound / Hydrocarbon derivative / Organonitrogen compound / Amine / Aromatic homopolycyclic compound
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
organic tricyclic compound (CHEBI:8597)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Norepinephrine:sodium symporter activity
Specific Function
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A2
Uniprot ID
P23975
Uniprot Name
Sodium-dependent noradrenaline transporter
Molecular Weight
69331.42 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
  4. Cheetham SC, Viggers JA, Butler SA, Prow MR, Heal DJ: [3H]nisoxetine--a radioligand for noradrenaline reuptake sites: correlation with inhibition of [3H]noradrenaline uptake and effect of DSP-4 lesioning and antidepressant treatments. Neuropharmacology. 1996 Jan;35(1):63-70. [PubMed:8684598]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. McDougle CJ, Epperson CN, Price LH, Gelernter J: Evidence for linkage disequilibrium between serotonin transporter protein gene (SLC6A4) and obsessive compulsive disorder. Mol Psychiatry. 1998 May;3(3):270-3. [PubMed:9672904]
  2. Rouillon F, Blachier C, Dreyfus JP, Bouhassira M, Allicar MP: [Pharmaco-epidemiologic study of the use of antidepressant drugs in the general population]. Encephale. 1996 May;22 Spec No 1:39-48. [PubMed:8767026]
  3. Frazer A, Daws LC: Serotonin transporter function in vivo: assessment by chronoamperometry. Ann N Y Acad Sci. 1998 Dec 15;861:217-29. [PubMed:9928259]
  4. Daws LC, Toney GM, Gerhardt GA, Frazer A: In vivo chronoamperometric measures of extracellular serotonin clearance in rat dorsal hippocampus: contribution of serotonin and norepinephrine transporters. J Pharmacol Exp Ther. 1998 Aug;286(2):967-76. [PubMed:9694957]
  5. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
  6. Kovachich GB, Aronson CE, Brunswick DJ: Effect of repeated administration of antidepressants on serotonin uptake sites in limbic and neocortical structures of rat brain determined by quantitative autoradiography. Neuropsychopharmacology. 1992 Dec;7(4):317-24. [PubMed:1476595]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Ibrahim S, Peggins J, Knapton A, Licht T, Aszalos A: Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. J Pharmacol Exp Ther. 2000 Dec;295(3):1276-83. [PubMed:11082465]

Drug created on June 13, 2005 07:24 / Updated on July 02, 2018 20:42